BEAM THERAPEUTICS INC.

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

12 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

05 Nov 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

29 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

06 Aug 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Transition of Chief Financial Officer

15 Jul 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

26 Jun 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

14 Jun 2024 02:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

30 May 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

14 May 2024 15:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

08 May 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

07 May 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

26 Mar 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

28 Feb 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

27 Feb 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

05 Feb 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

08 Jan 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

14 Dec 2023 05:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

08 Nov 2023 05:30:00 By Nasdaq GlobeNewswire